Hong Kong unveils next-gen drug for cancers associated with EpsteinâBarr virus Hong Kong unveils next-gen drug for cancers associated with EpsteinâBarr virus 03 March 2021 | News HKBU has established a spin-off company named BP InnoMed Limited (BPI) to further develop this new anti-EBV drug and carry out clinical trials Source: PR Newswire A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV.